Drug Profile
INV 064
Alternative Names: INV-064Latest Information Update: 29 Jun 2011
Price :
$50
*
At a glance
- Originator InVasc Therapeutics
- Class Anti-inflammatories
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic complications
Most Recent Events
- 29 Jun 2011 Discontinued - Phase-II for Diabetic complications in USA (unspecified route)
- 28 Apr 2008 Phase-II clinical trials in Diabetic complications in USA (unspecified route)